Program
ferric carboxymaltose
Also written as “Ferric Carboxymaltose (FCM)”, “Ferric carboxymaltose” and “Injectafer”.
Its studies are mostly in Anemia, Iron-Deficiency · Anemia · Iron Deficiencies · Restless Legs Syndrome · Heart Failure, led by 4 companies.
Drug pageFerric carboxymaltose: every studyAll 158 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Daiichi Sankyoits history only | 280 open or running | phase 4since Sep 23, 2013 | Apr 20, 2006 | none ahead |
| CSLits history only | 140 open or running | phase 4since Mar 29, 2010 | Aug 24, 2007 | none ahead |
| Sichuan Huiyu Pharmaceutical | 31 open or running | phase 1since Sep 27, 2023 | Sep 27, 2023 | none ahead |
| Novartisits history only | 10 open or running | phase 1since Dec 5, 2017 | Dec 5, 2017 | none ahead |
Also a collaborator on its studies: Suzhou Guochen Biotechnology, Boji Medical Technology, ClinStar, Cytel, Tigermed Consulting, Pierrel Research Europe, ICON Clinical Research, Parexel and SGS.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Sichuan Huiyu Pharmaceutical only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 27, 2023First study: phase 1 study in Iron DeficienciesFirst studyNCT06080555 · 84 enrolled · China
- Mar 20, 2025Phase 1 study in Healthy AdultNCT06895993 · 84 enrolled · China
- May 12, 2026Phase 1 study in Healthy AdultNCT07606105 · 70 planned · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 Sichuan Huiyu Pharmaceutical leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07606105Healthy Adult · China | 1 | Recruiting | Aug 26, 2026 | 70 |
| NCT06895993Healthy Adult · China | 1 | Completed | May 8, 2025 | 84 |
| NCT06080555Iron Deficiencies · China | 1 | Completed | Jan 22, 2024 | 84 |
How it is read
Names in the registry
- “Ferric Carboxymaltose (FCM)”, 13 entries
- “Ferric carboxymaltose”, 8 entries
- “Injectafer”, 5 entries
- “Ferric Carboxymaltose”, 5 entries
- “Ferric Carboxymaltose Injection”, 3 entries
Conditions, from the studies’ own filings
- Anemia, Iron-Deficiency, 17 studies
- Anemia, 12 studies
- Iron Deficiencies, 7 studies
- Restless Legs Syndrome, 4 studies
- Heart Failure, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.